Stay updated on Idasanutlin Combo Therapy in AML Clinical Trial
Sign up to get notified when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.

Latest updates to the Idasanutlin Combo Therapy in AML Clinical Trial page
- Check4 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now shows a 403 Forbidden error page instead of the study content, with boilerplate HTML and a 403 title, indicating an access issue when attempting to view the study entry.SummaryDifference0.5%

- Check25 days agoChange DetectedAccess to the study page now returns a 403 Forbidden error, replacing the expected study content and indicating restricted access to NCT03850535. The error page displays site chrome (header/footer) but no study details are visible.SummaryDifference23%

- Check46 days agoChange DetectedA new NIH grant/contract funding note was added to the page, and the site revision was updated to v3.6.6 (replacing v3.6.5), reflecting funding attribution and a version bump.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page now reflects a new revision version (v3.6.5), indicating a platform update rather than a change to the study information.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a small platform/template update; no substantive study information appears to have changed.SummaryDifference0.0%

Stay in the know with updates to Idasanutlin Combo Therapy in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.